MT-1

Melanotan I (MT-1, also known as afamelanotide or by the trade name Scenesse) is a synthetic tridecapeptide analog of the naturally occurring hormone alpha-melanocyte stimulating hormone (α-MSH), designed to provide photoprotection against ultraviolet radiation-induced skin damage.

MC1R Selectivity

Unlike Melanotan II (MT-2), MT-1 demonstrates high selectivity for the melanocortin-1 receptor (MC1R), which mediates melanogenesis in the skin. This selectivity results in skin darkening and photoprotective effects with minimal influence on other melanocortin receptors that mediate appetite, sexual function, and other processes.

Clinical Development

MT-1 was developed to pharmacologically stimulate melanogenesis, inducing a protective tan without requiring UV exposure. The peptide underwent extensive clinical development including Phase II and Phase III trials demonstrating efficacy and safety for erythropoietic protoporphyria (EPP).

Regulatory Approval

MT-1/afamelanotide achieved regulatory approval in Europe (2014), Australia (2014), and the United States (2019) as an orphan drug for EPP, representing one of the few synthetic peptides to achieve full regulatory approval for clinical use.

MT-1 exerts its effects through selective binding to and activation of the melanocortin-1 receptor (MC1R), a G-protein coupled receptor predominantly expressed on melanocytes in the basal layer of the epidermis.

Extended Half-Life

MT-1 was designed with specific amino acid modifications that confer resistance to enzymatic degradation, dramatically extending the half-life to several hours compared to natural α-MSH's minutes-long half-life.

Melanogenesis Pathway

When MT-1 binds to MC1R on melanocytes, it triggers a signaling cascade: elevated intracellular cAMP activates protein kinase A, which phosphorylates CREB transcription factor. This upregulates MITF expression, which increases melanogenic enzymes including tyrosinase, TRP-1, and TRP-2.

Photoprotective Mechanism

The resulting increased melanin production provides multiple photoprotective functions: absorbing UV radiation, neutralizing reactive oxygen species, shielding nuclear DNA from UV-induced damage, and dissipating UV energy as heat.

The research program for MT-1/afamelanotide represents one of the most comprehensive peptide development efforts, spanning over two decades from initial synthesis through regulatory approval.

Preclinical Studies

Early studies in the 1990s by researchers at the University of Arizona characterized MT-1's melanogenic properties and photoprotective effects. Animal studies demonstrated dose-dependent skin darkening and significant protection against UV-induced DNA damage and photocarcinogenesis.

Human Studies

Phase I trials established safety, pharmacokinetics, and proof-of-concept for melanogenesis induction. Studies showed that MT-1 produced eumelanin (the brown-black, photoprotective form) rather than pheomelanin, which was crucial for establishing its photoprotective effects.

EPP Clinical Trials

Phase II and III trials in EPP patients demonstrated that MT-1 implants significantly increased pain-free sun exposure time—patients could tolerate 3-7 times longer light exposure before experiencing phototoxic reactions. Multiple randomized controlled trials confirmed these benefits.

Beyond EPP

Research has explored MT-1 for other photodermatoses including polymorphic light eruption, as well as photoprotection in transplant recipients who face elevated skin cancer risk due to immunosuppression.

MT-1/afamelanotide has undergone extensive safety evaluation through clinical trials and post-marketing surveillance, establishing a well-characterized safety profile supporting regulatory approval.

Implant Site Reactions

The most common adverse events are related to the subcutaneous implant: site reactions including pain, erythema, swelling, and bruising occur frequently but are generally mild and self-limited.

Hyperpigmentation Effects

Darkening of skin, existing nevi (moles), freckles, and mucosal membranes is expected. Regular dermatological monitoring is recommended to avoid masking of melanoma or other skin lesions.

Systemic Effects

Systemic adverse events have generally been mild, including nausea, headache, and fatigue. The selectivity for MC1R means appetite effects and sexual function effects seen with MT-2 are minimal or absent with MT-1.

Long-Term Safety

Long-term data extending over years of treatment shows no cumulative toxicity or progressive adverse effects. The benefit-risk profile for EPP is highly favorable, transforming quality of life for patients with this debilitating condition.